Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

Phase 2 Active, not recruiting NCT02314169

Summary

This phase II trial studies how well nivolumab with or without ipilimumab works in treating patients with anal canal cancer that has not responded to previous treatment (refractory) and that has spread from where it first started (primary site) to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Overall Response Rate: Number of Participants With Response (Part A)

Up to 2 years · percentage of patients with a response

Progression-free Survival (PFS) (Part B)

Time period from the date of randomization to the date of PD or death whichever occurred first, assessed up to 2 years · months

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

• CryoBalloon Ablation for Treatment of Duodenal Adenomas — Johns Hopkins University
• Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refract — Jennerex Biotherapeutics
• Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III — National Cancer Institute (NCI)
• Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps — National Cancer Institute (NCI)
• Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating — National Cancer Institute (NCI)
• Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 — National Cancer Institute (NCI)

All trials